Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

NEXT STORY
Global Infectious Disease Diagnostics Market Report 2021-2026: Products (Reagents, Assays, Instrument), Test (Laboratory, POC), Technology (Immunodiagnostics, Microbiology, PCR, NGS, INAAT)
PREV STORY
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting 2018

author_avatar
NASDAQ Market News

Kura Oncology to Report Third Quarter 2018 Financial Results

SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a ...

author_avatar
NASDAQ Market News

Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy

author_avatar
NASDAQ Market News